Antioxidants in Huntington's disease

Area of Science:

• Neuroscience
• Genetics
• Biochemistry

Background:

• Huntington's disease (HD) is a neurodegenerative disorder characterized by selective neuronal loss, leading to motor, cognitive, and psychiatric impairments.
• HD stems from a cytosine-adenine-guanine (CAG) repeat expansion in the huntingtin gene, producing a mutant huntingtin protein with a toxic gain of function.
• This mutant protein triggers neuronal dysfunction and death through mechanisms including transcriptional impairment, excitotoxicity, oxidative damage, inflammation, apoptosis, and mitochondrial dysfunction.

Purpose of the Study:

• To explore the role of peroxisome proliferator-activated receptor gamma coactivator-1α (PGC-1α) in Huntington's disease pathogenesis.
• To investigate the contribution of oxidative damage to Huntington's disease progression.
• To identify potential therapeutic strategies targeting oxidative stress and PGC-1α pathways for Huntington's disease.

Main Methods:

• Review of existing literature on Huntington's disease mechanisms, focusing on PGC-1α and oxidative stress.
• Analysis of the implications of impaired PGC-1α expression and function in HD.
• Examination of the role of oxidative damage to lipids, proteins, and DNA in HD pathogenesis.

Main Results:

• Impaired PGC-1α expression and function are implicated in Huntington's disease, increasing vulnerability to oxidative stress and striatal degeneration.
• Significant oxidative damage to cellular components, including DNA, is a recognized feature of HD, potentially contributing to CAG repeat expansion.
• Elevated oxidized DNA bases in patient plasma may serve as a biomarker for disease progression.

Conclusions:

• Restoring PGC-1α function and enhancing antioxidant enzyme expression are promising therapeutic avenues for slowing Huntington's disease progression.
• Modulating the Nrf-2/ARE pathway or increasing PGC-1α expression could represent effective strategies for treating Huntington's disease.
• Antioxidant treatments have shown efficacy in preclinical models and hold promise for human clinical trials in Huntington's disease.